Regeneron (REGN) (MDC) (MNST) (MOVE) (DSW) (TSM) (ZNGA) Ratings, Price Targets

Regeneron Pharma (NASDAQ: REGN), MDC Holdings (NYSE: MDC), Monster Beverage Corp. (NASDAQ: MNST), Move Inc. (NASDAQ: MOVE), DSW Inc. (NYSE: DSW), Taiwan Semiconductor Mfg. Co. Ltd. (NYSE: TSM) and Zynga Inc. (NASDAQ: ZNGA) ratings and price targets.

Regeneron Pharma (REGN) had its price target raised by Deutsche Bank (NYSE:DB) to $80.00. They have a “buy” rating on the firm.

MDC Holdings (MDC) was downgraded by Zacks Investment Research from a “neutral” rating to an “underperform” rating.

Monster Beverage Corp. (MNST) was downgraded by Zacks Investment Research from an “outperform” rating to a “neutral” rating.

Move Inc. (MOVE) was downgraded by Zacks Investment Research from a “neutral” rating to an “underperform” rating.

DSW Inc. (DSW) was upgraded by Zacks Investment Research from a “neutral” rating to an “outperform” rating.

Taiwan Semiconductor Mfg. Co. Ltd. (TSM) had its “buy” rating reiterated by Nomura (NYSE:NMR).

Zynga Inc. (ZNGA) is now covered by Pacific Crest. They have a “sector perform” rating on the firm.

CSX (CSX) (QLTY) (RAIL) (REGN) (CNI) (DECK) Ratings Reiterated

CSX Corp. (NYSE: CSX), Quality Distribution, Inc. (NASDAQ: QLTY), FreightCar America, Inc. (NASDAQ: RAIL), Regeneron Pharma (NASDAQ: REGN), Canadian National Railway (NYSE: CNI) and Deckers Outdoor (NASDAQ: DECK) had ratings on them reiterated by analysts.

Jefferies Group (NYSE:JEF) reiterated its “Hold” rating on Quality Distribution, Inc. (QLTY).

Jefferies Group reiterated its “Buy” rating on FreightCar America, Inc. (RAIL).

Brean Murray reiterated its “Buy” rating on Regeneron Pharma (REGN).

Jefferies Group reiterated its “Hold” rating on Canadian National Railway (CNI).

Jefferies Group reiterated its “Buy” rating on CSX Corp. (CSX).

Jefferies Group reiterated its “Buy” rating on Deckers Outdoor (DECK).

Tenaris (TS) (ENR) (FTI) (HOGS) (HOT) (REGN) Downgraded

Tenaris (NYSE: TS), Energizer Holdings, Inc. (NYSE: ENR), FMC Tech (NYSE: FTI), ZHONGPIN INC. (NASDAQ: HOGS), Starwood Hotels (NYSE: HOT) and Regeneron Pharmaceuticals (NASDAQ: REGN) downgraded by analysts.

Tenaris (TS) was downgraded by Guggenheim from a “Buy” rating to a “Neutral” rating.

Energizer Holdings, Inc. (ENR) was downgraded by Standpoint Research from a “Buy” rating to a “Hold” rating.

FMC Tech (FTI) was downgraded by Guggenheim from a “Buy” rating to a “Neutral” rating.

ZHONGPIN INC. (HOGS) was downgraded by Global Hunter Securities from a “Neutral” rating to a “Reduce” rating.

Starwood Hotels (HOT) was downgraded by Morgan Stanley (NYSE:MS) from an “Overweight” rating to an “Equal Weight” rating. They have a price target of $47.00 on the company, down from $71.00.

Regeneron Pharmaceuticals (REGN) was downgraded by Citigroup (NYSE:C) from a “Buy” rating to a “Hold” rating. They have a price target of $60.00 on the company.

Janus Capital (JNS) (REGN) (RIMM) (WDR) Ratings Changed

Janus Capital (NYSE:JNS), Regeneron Pharmaceuticals (NASDAQ:REGN), Research In Motion (NASDAQ:RIMM) and Waddell & Reed (NYSE:WDR) had their ratings adjusted by analysts.

Janus Capital (JNS) is now rated new Buy at Jefferies (NYSE:JEF). They have a price target of $8 on the company.

Regeneron Pharmaceuticals (REGN) was downgraded by Citigroup (NYSE:C) from "Buy" to "Hold." They have a price target of $60 on the company.

Research In Motion (RIMM) was upgraded by Sterne Agee from "Neutral" to "Buy." They have a price target of $35 on the company.

Waddell & Reed (WDR) was rated new Buy by Jefferies. They have a price target of $34 on the company.

CNOOC (CEO) (HLS) (PPBI) (SYMC) (AXTI) (AXTI) (LVLT) (REGN) Upgraded

CNOOC (NYSE: CEO), HealthSouth (NYSE: HLS), Pacific Premier Bancorp, Inc. (NASDAQ: PPBI), Symantec (NASDAQ: SYMC), AXT, Inc. (NASDAQ: AXTI), Level 3 (NASDAQ: LVLT) and Regeneron Pharmaceuticals (NASDAQ: REGN) upgraded by analysts.

CNOOC (CEO) was upgraded by UBS AG (NYSE:UBS) from a “Neutral” rating to a “Buy” rating.

HealthSouth (HLS) was upgraded by JMP Securities from a “Market Perform” rating to an “Outperform” rating.

Pacific Premier Bancorp, Inc. (PPBI) was upgraded by Sterne Agee from a “Neutral” rating to a “Buy” rating. They have a price target of $8.70 on the company.

Symantec (SYMC) was upgraded by Wunderlich from a “Hold” rating to a “Buy” rating. They have a price target of $22.00 on the company, up from $21.00.

AXT, Inc. (AXTI) was upgraded by Needham & Company from a “Hold” rating to a “Buy” rating. They have a price target of $11.00 on the company.

Level 3 (LVLT) was upgraded by Raymond James (NYSE:RJF) from an “Underperform” rating to a “Market Perform” rating.

Regeneron Pharmaceuticals (NASDAQ: REGN) was upgraded by RBC Capital from a “Sector Perform” rating to an “Outperform” rating. The have a price target of $70.00 on the company.

Price Targets on (REGN) (SD) (TCB) (TESO) (VQ) Updated

Analysts updated their price targets on Regeneron Pharma (NASDAQ: REGN), SandRidge Energy Inc. (NYSE: SD), TCF Financial Co. (NYSE: TCB), Tesco Co. (NASDAQ: TESO) and Venoco, Inc. (NYSE: VQ) today.

Needham & Company raised their price target on Regeneron Pharms (REGN) from $49.00 to $60.00. They have a “buy” rating on the company.

Bank of America (NYSE:BAC) raised their price target on SandRidge Energy Inc. (NYSE: SD) from $10.00 to $11.00.

Compass Point raised their price target on TCF Financial Co. (TCB) from $14.00 to $16.00. They have a “neutral” rating on the company.

FBR Capital raised their price target on Tesco Co. (TESO) from $22.00 to $25.00. They have an “outperform” rating on the company.

Jefferies (NYSE:JEF) cut their price target on Venoco, Inc. (VQ) from $18.50 to $16.00.

Big Movers (FLS) (LSTZA) (REGN) (EOG) (SINA) on May 6

Among the big, positive movers on Friday, May 6, were Flowserve Corp. (FLS), Liberty Media Corp. (LSTZA), Regeneron Pharmaceutical (REGN), Eog Resources (EOG) and Sina Corp. (SINA).

Flowserve Corp. (FLS) jumped $3.32, to close at $122.55, a gain of 2.78 percent.

Liberty Media Corp. (LSTZA) was up $3.24 on the day to close at $77.49, a gain of 4.36 percent.

Regeneron Pharmaceutical (REGN) climbed $3.20 to close at $50.25, a gain of 6.80 percent.

Eog Resources (EOG) rose $3.09 to close the session at $107.44, a gain of 2.96 percent.

Sina Corp. (SINA) was up $2.93 to end the day at $125.19, a gain of 2.40 percent.

Praxair (PX) (REGN) (RNOW) (RNR) (RRC) Price Targets Raised

Price targets on Praxair, Inc. (NYSE: PX), Regeneron Pharms (NASDAQ: REGN), RightNow Technologies (NASDAQ: RNOW), RenaissanceRe Holdings Ltd. (NYSE: RNR) and Range Resources (NYSE: RRC) raised by analysts.

Jefferies (NYSE:JEF) raised their price target on Praxair, Inc. (PX) from $113.00 to $122.00. They have a “buy” rating on the company.

RBC Capital raised their price target on Regeneron Pharms (REGN) from $48.00 to $70.00. They have an “outperform” rating on the company.

Needham & Company raised their price target on RightNow Technologies (RNOW) from $31.00 to $36.00. Theyhave a “buy” rating on the company.

RBC Capital raised their price target on RenaissanceRe Holdings Ltd. (RNR) from $68.00 to $73.00. They have a “sector perform” rating on the company.

RBC Capital raised their price target on Range Resources (RRC) from $68.00 to $70.00. They have an “outperform” rating on the company.

Illumina (ILMN) (GPK) (SNN) (REGN) Get Coverage Initiations from Analysts

Illumina, Inc. (NASDAQ: ILMN), Graphic Packaging Holding Company (NYSE: GPK), Smith & Nephew plc (NYSE: SNN) and Regeneron Pharms (NASDAQ: REGN) now getting coverage initiated by these analysts.

Goldman Sachs (NYSE:GS) initiated coverage on Graphic Packaging Holding Company (GPK). They started them with a “Buy” rating and a price target of $6.25 a share.

Bank of America (NYSE:BAC) initiated coverage on Smith & Nephew plc (SNN). They started them with a “Neutral” rating.

Auriga initiated coverage on Illumina, Inc. (ILMN). They started them off with a “Buy” rating and a price target of $75.

Boenning & Scattergood initiated coverage on Regeneron Pharms (REGN). They started them with an “Outperform” rating and a price target of $58.

Regeneron (REGN) (HSP) (SYMC) (CMI) (CPLA) get Ratings Initiations

Regeneron Pharms (NASDAQ:REGN), Hospira (NYSE:HSP), Symantec (NASDAQ:SYMC), Cummins (NYSE:CMI) and Capella Education (NASDAQ:CPLA) had analysts initiate coverage on them.

Regeneron Pharms (REGN) was started off with an "Overweight" rating by Barclays Capital, which has a price target of $64 on the company.

Hospira (HSP) was started off with an "Overweight" rating by Barclays Capital, with a price target of $64.

Symantec (SYMC) was initiated with a "Buy" rating by UBS (NYSE:UBS), with a price target of $22 on them.

Cummins (CMI) was initiated at a "Buy" rating by UBS, with a price target of $135.

Capella Education (CPLA) was started off with a "Sector Perform" rating by RBC Capital, which placed a price target of $52 on the company.

Perry Ellis (PERY) (REGN) (MSTR) (QLIK) Get Ratings Initiations

Regeneron Pharmceuticals (NASDAQ:REGN), MicroStrategy (NASDAQ:MSTR), Qlik Tech (QLIK) and Perry Ellis (NASDAQ:PERY) all had rating initiated on them from several brokerages.

Regeneron Pharmceuticals (REGN) has coverage resumed on them from Boenning & Scattergood, which started them off with an "Outperform" rating. They placed a price target of $58 on REGN.

MicroStrategy (MSTR) had coverage initiated on them by BMO Capital Markets, which started them off with an "Outperform.' They have a price target of $180 on MicroStrategy.

Qlik Tech (QLIK) also had coverage initiated on them by BMO Capital Markets, receiving a "Market Perform" rating from them. They placed a price target of $29 on Qlik.

Deutshe Bank (NYSE:DB) initiated coverage on Perry Ellis (PERY), starting them off with a "Buy" rating.

Regeneron Pharma (NASDAQ:REGN) Has Strong Short and Long Term Catalysts

Regeneron Pharma (NASDAQ:REGN) looks like they're positioned well for short- and long-term growth, with a mixture of products adding to the overall success of the company.

Needham noted, "In the near-term, we believe the data presentations and submissions for VEGF Trap-Eye in AMD and Phase 3 RILONACEPT data in gout prevention will provide significant catalysts to the stock. In the long-term, we believe data from the oncology program, progress of early stage mAb programs, and the evergreen technology platform will serve to drive the long-term growth of the Company."

Needham & Company reiterates a "Buy" on Regeneron Pharma, which closed Wednesday at $33.29, up $0.03, or 0.11 percent. Needham has a price target of $39 on them.

Regeneron (Nasdaq:REGN), Sanofi-Aventis' (NYSE:SNY) REGN475 Put on Hold by FDA

Citing possible damage to the bones of patients using the drug REGN475, aka SAR164877, the FDA told Regeneron (Nasdaq:REGN) and Sanofi-Aventis (NYSE:SNY) the drug study must be put on hold.

The drug was in the trial stage for the purpose of blocking pain in those suffering from osteoarthritis; it's supposed to be a nerve growth factor inhibitor.

The Food and Drug Administration revealed the decision in a filing with the Securities and Exchange Commission, saying a patient being treated with the drug developed avascular necrosis of a joint. That refers to a the bone collapsing after bone tissue dies.

The FDA made the decision because of their concerns over the possibility the overall class of drugs having the potential to generate the side effect.

Sanofi-Aventis was trading at $32.13, down $0.37, or 1.14 percent, as of 1:38 PM EST. Regeneron Pharmaceuticals was trading at $33.66, up $0.16, or 0.48 percent.

Regeneron Pharma (NASDAQ:REGN) Gets Positive Phase III Data for VEGF-TRAP

Regeneron Pharma (NASDAQ:REGN) received positive phase III data for VEGF-TRAP in CRVO and updated phase II data in DME, generating a positive reaction from Barclays (NYSE:BCS).

They said, "We are maintaining our OW rating on REGN following release of positive phase III data for VEGF-TRAP in CRVO and updated phase II data in DME. Data support a best-in-class profile demonstrated previously in the VIEW studies for AMD and should ensure dominant positioning in the anti-VEGF retinal disease space."

Barclays maintains an "Overweight" on Regeneron Pharma, which closed Tuesday at $33.65. Barclays has a price target on them of $48.

Regeneron Pharma's (NASDAQ:REGN) VEGF Trap-Eye Solution Works!

After two late-stage tests on Regeneron Pharma's (NASDAQ:REGN) and Bayer's VEGF Trap-Eye solution were successfully completed, the results were it worked as good as Roche’s ranibizumab (Lucentis), which they are sure to take market share away from when it hits the market.

Canaccord said, "Regeneron spiked early Monday after the drug developer and partner Bayer AG said their potential injectable treatment for the eye disease wet age-related macular degeneration worked as well as Roche’s ranibizumab (Lucentis) in two late-stage studies. The companies are developing the VEGF Trap-Eye solution as a treatment for the disease, which results in vision loss as new blood vessels grow beneath the retina and leak blood and fluid, damaging the retina and distorting vision. The condition, which can progress to blindness, usually affects older adults. Analysts at Brean Murray note that giving VEGF Trap Eye every two months was at least as good as monthly 0.5 mg ranibizumab, which halves the number of undesirable intraocular injections. Patient vision generally suffers as one tries to minimize their number of eye injections by seeking therapy only when they deem their visual acuity to be low. Therefore, a less frequent therapy that is at least as effective as ranibizumab is
extremely desirable and should garner significant market share."

Regeneron closed Tuesday at $29.99, rising by $0.46, or 1.56 percent.